Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products; Guidance for Industry - Draft Guidance

An individual expresses strong opposition to the proposed guidance based on ethical concerns regarding animal testing. The commenter argues that animal suffering should be eliminated and suggests using human subjects instead.

An individual expresses strong opposition to the proposed guidance based on ethical concerns regarding animal testing. The commenter argues that animal suffering should be eliminated and suggests using human subjects instead.

The commenter supports the move toward streamlined nonclinical safety studies by arguing that animal testing is often ineffective and morally wrong. They advocate for the abandonment of animal testing in favor of non-animal protocols.

An individual commenter opposes the proposed guidance, expressing strong emotional distress over the use of animals in drug testing. They advocate for a transition to non-animal testing technologies and suggest using human prisoners as an alternative.

The commenter, identifying as a regular person, opposes the proposed guidance due to ethical concerns regarding animal testing. They argue that animal testing is often inaccurate for humans and advocate for an end to the treatment of animals as property in laboratories.

An individual commenter expresses strong opposition to animal testing and urges the agency to stop it, citing the ineffectiveness of animal models and ethical concerns regarding animal welfare. The commenter supports the proposed action's goal of streamlining nonclinical safety studies, as it moves toward reducing reliance on animal testing.

An individual is requesting that the agency end animal testing, arguing that it is cruel and that modern technology should provide alternatives. The commenter advocates for a shift toward cruelty-free products and practices.

The commenter opposes the proposed guidance because it involves animal testing, which they believe is cruel and violates the rights of sentient beings. They advocate for a change in the law to stop all animal testing.

An individual commenter advocates for the reduction of animal testing in pharmaceutical research, urging the FDA to consider alternative methodologies and technologies. They support the proposed action's goal of streamlining nonclinical safety studies by highlighting the public's growing opposition to animal experimentation.